Rubén E Mújica-Mota

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5951284/publications.pdf

Version: 2024-02-01

		1163117	1125743
16	179	8	13
papers	citations	h-index	g-index
16	16	16	375
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Incorporating Equity Concerns in Cost-Effectiveness Analyses: A Systematic Literature Review. Pharmacoeconomics, 2022, 40, 45-64.	3.3	13
2	New horizons in evidence-based care for older people: individual participant data meta-analysis. Age and Ageing, 2022, 51, .	1.6	7
3	Accounting for Heterogeneity in Resource Allocation Decisions: Methods and Practice in UK Cancer Technology Appraisals. Value in Health, 2021, 24, 995-1008.	0.3	2
4	The heterogeneous causal effects of neonatal care: a model of endogenous demand for multiple treatment options based on geographical access to care. Health Economics (United Kingdom), 2020, 29, 46-60.	1.7	2
5	Trends in time to cancer diagnosis around the period of changing national guidance on referral of symptomatic patients: A serial cross-sectional study using UK electronic healthcare records from 2006–17. Cancer Epidemiology, 2020, 69, 101805.	1.9	29
6	Predicting incident delirium diagnoses using data from primary-care electronic health records. Age and Ageing, 2020, 49, 374-381.	1.6	7
7	Health-related quality of life in neuroendocrine neoplasia: a critical review. Endocrine-Related Cancer, 2020, 27, R267-R280.	3.1	7
8	Do time trade-off values fully capture attitudes that are relevant to health-related choices?. European Journal of Health Economics, 2019, 20, 559-568.	2.8	1
9	Three biomarker tests to help diagnose preterm labour: a systematic review and economic evaluation. Health Technology Assessment, 2019, 23, 1-226.	2.8	8
10	Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 2018, 22, 1-326.	2.8	21
11	A framework to address key issues of neonatal service configuration in England: the NeoNet multimethods study. Health Services and Delivery Research, 2018, 6, 1-160.	1.4	14
12	Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil. BMC Gastroenterology, 2017, 17, 119.	2.0	6
13	Cost-effectiveness of timely versus delayed primary total hip replacement in Germany: A social health insurance perspective. Orthopedic Reviews, 2017, 9, 7161.	1.3	13
14	The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and) Tj ETQq0 0 0 rgBT /O 1-588.	Overlock 10 2.8	0 Tf 50 232 To 15
15	A systematic review and economic evaluation of intraoperative tests [RD-100i one-step nucleic acid amplification (OSNA) system and Metasin test] for detecting sentinel lymph node metastases in breast cancer. Health Technology Assessment, 2015, 19, 1-216.	2.8	33
16	Stated preferences for anti-malarial drug characteristics in Zomba, a malaria endemic area of Malawi. Malaria Journal, 2014, 13, 259.	2.3	1